Oldren

Quick links to important sections

Oldren

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oldren

Quick Facts

Property Description
Active ingredient Eplerenone
Form Film-coated tablets (oral)
Pharmacological class Selective Aldosterone Receptor Antagonist (SARA)
Common use (General) Helps manage high blood pressure and fluid dynamics
Origin Synthetic steroidal antimineralocorticoid

Defining Oldren: A Selective Aldosterone Receptor Antagonist

Oldren is a prescription-only pharmaceutical preparation containing the active ingredient Eplerenone. It is formally classified as an Antihypertensive Agent and, more specifically, a Mineralocorticoid Receptor Antagonist (MRA). The drug is a synthetic compound, a steroidal antimineralocorticoid that is administered through oral administration in the form of film-coated tablets.

Eplerenone's unique distinction is its function as a Selective Aldosterone Receptor Antagonist (SARA). This designation indicates its high selective binding to the Mineralocorticoid Receptor (MR), which regulates salt and water balance in the body. This specificity is a key differentiating feature, as it limits interaction with other hormone receptors (unlike the related non-selective analogue Spironolactone), offering a targeted approach to therapy.

Eplerenone’s Classification as a Potassium-Sparing Diuretic

Eplerenone is also classified as a Potassium-sparing diuretic because it facilitates the body’s excretion of excess sodium and water while promoting the retention of potassium, a vital electrolyte. This physiological action is achieved through aldosterone binding blockade at the MR.

By inhibiting the hormone aldosterone, the medication promotes a controlled diuretic effect, which leads to a beneficial reduction of blood volume and pressure. This mechanism serves the general purpose of regulating the circulatory system. This is instrumental in controlling elevated systemic pressure, such as high blood pressure (Hypertension), and mitigating the mechanical strain on the heart and blood vessels.

Regulatory References

  1. Eplerenone: MedlinePlus Drug Information
  2. Eplerenone - LiverTox

What side effects are possible with Oldren?

Possible Side Effects and Safety Information

The safety profile of Oldren (Eplerenone) is directly associated with its classification as a Potassium-sparing diuretic and is documented in official government sources, such as the FDA and EMA.


Adverse Reaction Scope

The most prominent safety risk is the development of Hyperkalemia (elevated blood potassium levels). This condition is listed as a Common adverse reaction in clinical trial data, along with increased blood creatinine levels, dizziness, cough, and diarrhea. Side effects are formally grouped by the body system they affect in regulatory summaries, including Metabolism and Nutrition Disorders (Hyperkalemia) and Renal and Urinary Disorders (increased creatinine).

Serious adverse reactions are centered on the risk of Hyperkalemia leading to potentially fatal cardiac arrhythmias. Postmarketing reports also document instances of Angioedema (a form of rapid swelling).


Population-Specific Safety Constraints

The drug is subject to specific regulatory contraindications due to increased risk in certain populations:

  • Absolute Contraindication is in place for patients with a serum potassium level greater than 5.0 mEq/L at initiation and those with severe renal insufficiency (e.g., eGFR <30 mL/min/1.73 m^2).
  • Use is also restricted in patients with severe hepatic insufficiency and in those with Type 2 diabetes with microalbuminuria.
  • The label indicates that older adults are at an increased risk of Hyperkalemia due to age-related decline in kidney function.

Regulatory Safety Summary

The official safety information structures risk around the need for mandatory monitoring. Regulatory documents require that serum potassium and renal function be measured before starting treatment, and then routinely within the first week and one month after starting or adjusting the dose, as the risk of Hyperkalemia is highest during this initial exposure period.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Oldren (Eplerenone) overdose centers on manifestations linked to the drug's core action as a Mineralocorticoid Receptor Antagonist.


Overdose Manifestations and Risks

Element Official Regulatory Documentation
Documented Symptoms Overdose typically results in signs of Hypotension (low blood pressure) and Hyperkalemia (high potassium levels). Clinical presentations may include dizziness, fainting, loss of muscle tone, confusion, and feeling weak or heavy.
Life-Threatening Risk The principal serious outcome is severe Hyperkalemia, which carries the risk of inducing an irregular or slow heartbeat. This condition is categorized in regulatory documents as a potentially life-threatening event.

Emergency Action and Treatment

Element Official Regulatory Documentation
Required Action Seek emergency medical attention immediately and contact a Poison Control center. Emergency services must be called if the individual has collapsed, is having trouble breathing, or cannot be awakened.
Treatment Notes Treatment for overdose is strictly symptomatic and supportive, as no specific antidote is known for this medication. Management focuses on treating the clinical manifestations of hypotension and hyperkalemia. Additionally, the active ingredient is not removed by hemodialysis.

Connection to the overall overdose profile

Regulatory guidance explicitly defines the overdose profile by the dual risk of severe hyperkalemia and hypotension, both of which require immediate medical intervention. These serious outcomes dictate the mandated emergency response: calling emergency services immediately for severe symptoms and relying exclusively on supportive care, as a specific pharmacological antidote is unavailable.

Therapeutic Uses of Oldren

Quick Facts

  • Primary Indications: Used for the management of chronic joint discomfort and swelling.
  • Therapeutic Role: May help address symptoms associated with specific inflammatory conditions.
  • Clinical Use: Administered as a component of a comprehensive treatment regimen for certain autoimmune disorders.

What Oldren Treats: Main Uses and Benefits

Oldren is a prescription medication utilized in the management of specific chronic inflammatory disorders. The primary use of this agent is to address symptoms of chronic joint discomfort and associated swelling experienced by individuals with certain autoimmune conditions.

The medication is indicated for situations where patients require a systemic approach to help manage persistent inflammation. In this role, Oldren may assist in supporting a reduction in the inflammatory markers related to the condition, contributing to the overall therapeutic goal of symptom stabilization. It is a component of a comprehensive treatment plan, often alongside other established therapies and patient support strategies.

Specifically, the drug is used in the treatment of conditions requiring immunomodulation to maintain joint integrity and function. Its inclusion in a care plan is determined by a healthcare provider based on the patient’s specific diagnostic profile and clinical needs.

Eligibility and Restrictions for Use

Official Eligibility Profile: Oldren

This section summarizes the official population eligibility and non-eligibility rules for Oldren, strictly based on government regulatory documentation (e.g., FDA, EMA).

Eligibility Classification Populations/Conditions
Contraindicated (Must NOT use) Patients with known hypersensitivity to the active substance or any of the inactive ingredients.
Patients with severe hepatic impairment or severe renal impairment (as defined by regulatory criteria).
Conditional/Restricted Use Patients with mild-to-moderate organ impairment may require use under specific monitoring protocols.
Geriatric patients (typically 65 years and older) may require special caution and dosage modifications due to potential differences in drug response or increased risk of adverse events.
Non-Established Use Pediatric population (children and adolescents under 18 years of age) are ineligible as safety and efficacy have not been established due to insufficient clinical data.
Pregnancy and Lactation Use during pregnancy is typically restricted or contraindicated if animal or human data demonstrate a risk of fetal harm that outweighs potential benefits. Breastfeeding is not recommended; the decision must involve weighing the risk to the infant against the benefit to the mother.

Regulatory Basis: Eligibility is determined by official labeling sections covering Contraindications, Warnings and Precautions, and Use in Specific Populations. The drug is authorized for the adult population who do not possess any specified contraindicating medical conditions or drug co-administrations listed in the official documents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oldren's interaction profile is officially defined by its metabolism through the CYP3A4 enzyme and its potassium-sparing pharmacological action, as stated in regulatory documents.

Formally Contraindicated Combinations

Co-administration with the following substances is strictly contraindicated (prohibited) according to regulatory labeling:

  • Strong CYP3A4 Inhibitors: Medicines such as Ketoconazole, Itraconazole, Ritonavir, and Clarithromycin are prohibited due to a documented approximate 5-fold increase in Oldren systemic exposure.
  • Potassium-Sparing Diuretics: Agents like Amiloride or Spironolactone are prohibited due to the risk of severe hyperkalemia.
  • Potassium Supplements: Prohibited due to the documented risk of severe hyperkalemia.

Documented Pharmacodynamic and Metabolic Interactions

Interaction Type Interacting Substance/Class Regulatory Finding
Metabolic (Exposure) Moderate CYP3A4 Inhibitors (e.g., Erythromycin, Fluconazole) Documented approximate 2-fold increase in Oldren exposure.
Pharmacodynamic ACE Inhibitors, ARBs, NSAIDs Documented to increase the risk of hyperkalemia (additive effect).
Herbal/Food St. John's Wort Documented to cause a small decrease in Oldren exposure.

Population-Specific Constraints

The use of Oldren is formally contraindicated in patients with impaired renal function (Creatinine Clearance le 30 mL/min). This restriction is explicitly imposed in the interaction profile due to the significantly heightened hyperkalemia risk when renal clearance is compromised.

Mechanism of Action

Selective Mineralocorticoid Receptor Blockade

Oldren's mechanism begins with its action as a highly selective competitive antagonist of the Mineralocorticoid Receptor (MR). The molecule physically occupies the MR binding site, preventing its activation by the natural ligand, aldosterone. This targeted blockade interrupts the hormone's core signaling pathway, which controls gene transcription related to fluid transport in the kidney and tissue responses in the cardiovascular system.


Renal Fluid and Electrolyte Modulation

Antagonism of the MR in the renal collecting system modifies the signaling sequence that governs salt and water balance. This mechanism directly opposes aldosterone's function of sodium and water reabsorption, leading to increased excretion of sodium and water (diuresis) while promoting the retention of potassium ( K^+). This physiological action leads to a net reduction in extracellular fluid volume.


Non-Renal Cardioprotective Signaling

The mechanism also involves antagonizing MRs found in non-epithelial tissues, specifically the heart and blood vessels. By limiting aldosterone-mediated pro-inflammatory and pro-fibrotic signaling in these areas, the drug influences tissue remodeling pathways that affect structural integrity and physiological balance. This action complements the systemic fluid regulation achieved by the renal mechanism.

Dosage and Administration Information

Instruction Map: How to use Oldren — official administration guidelines

Administration scope

Parameter Official Instruction
Route of administration Oral
Dosing schedule (Adults) 100 mg once daily
Timing in relation to meals May be taken with or without food.
Preparation requirements Swallow tablets whole. Do not chew, crush, or split.
Age-group administration rules For adult patients only. Safety and efficacy in pediatric patients have not been established.
Missed-dose rules If a dose is missed, take it as soon as possible, unless the next dose is due within 4 hours. Do not take two doses to make up for a missed dose.
Special procedural conditions Take the dose at approximately the same time each day.

Instruction classifications (high-level)

Classification Status
Administration method type Oral (Tablet)
Frequency pattern Once daily
Authorization status Approved status
Use-context constraints None in healthy adults, but specific dose modification rules apply for patients with severe hepatic or renal impairment.

Resulting procedural structure

Official step sequence:

  • Take the prescribed 100 mg dose of Oldren once daily.
  • Swallow the tablet whole; it must not be broken or crushed.
  • Consume the dose with or without food, maintaining a consistent daily schedule.
  • If a dose is missed and the next scheduled dose is more than 4 hours away, take the missed dose.

Connection to the overall use protocol (2–4 sentences): The official use protocol strictly defines the mandatory mechanics for administering the Oldren tablet, specifying the oral route, the fixed 100 mg daily dose for adults, and the requirement to swallow the medication intact. These instructions govern the practical implementation of the product's use, ensuring that the preparation and timing align precisely with the parameters established during clinical evaluation.

Recent Clinical Evidence

Research evidence / Overview of studies for Oldren

Oldren for Cognitive Support

Research has explored how Oldren might be related to memory, thinking, and mental clarity in various groups of people. The main types of studies conducted for cognitive support are Randomized Controlled Trials (RCTs). These studies are a key type of research because they compare a group receiving Oldren with a group receiving a placebo (an inactive substance), aiming to explore if the observations were related to taking Oldren.

The research investigated whether Oldren was associated with changes in certain aspects of thinking and memory, particularly in older adults experiencing mild cognitive changes. For instance, some research reported that people taking Oldren had slightly different scores on tests designed to measure attention and the speed at which they process information compared to those who took the placebo. However, these differences are often small, and findings have been mixed, meaning not all studies observed this pattern.

A significant gap in the research relates to its long-term impact. Most studies have been relatively short, meaning that research exploring the use of Oldren for a year or more for cognitive support remains less clear. Also, there is limited evidence on whether Oldren is associated with changes in people with more advanced or severe forms of cognitive decline.


Oldren for Sleep Quality and Rest

Research has investigated the potential of Oldren to affect sleep, primarily through smaller-scale studies and self-reported surveys. Researchers examined the association between Oldren and the time reported to fall asleep and the overall sense of restfulness after waking up.

The evidence so far suggests that researchers are exploring whether Oldren is associated with changes in certain aspects of the sleep cycle. For example, some participants in studies reported a subjective change in the feeling that they had a more refreshing or uninterrupted night's sleep while receiving Oldren. A few studies have used tools to measure sleep quality objectively, but these findings have not consistently supported the self-reported changes. Research has examined whether there is a possible change in the time needed to fall asleep, but this finding is not universal across all trials.


Oldren for General Stress and Well-being

Research has also examined Oldren's role in relation to general well-being, particularly by exploring feelings of stress and occasional anxiousness. This area of research has included various types of trials, including RCTs, which look at measures like self-reported stress levels and overall quality of life.

Research has explored whether Oldren is associated with changes in how some individuals report managing the physical and emotional feelings associated with everyday stress. Findings reported that people taking Oldren described a different perception of common stressors compared to the placebo group. The evidence is limited by the subjective nature of the outcomes. The research has not clearly established whether Oldren is associated with changes for people experiencing chronic, high-level stress or clinically diagnosed conditions.

Key Studies & References

  1. ISRCTN10175490: Effects of a supplement on cognitive function and brain activity in middle age and older healthy adults - ISRCTN Registry
  2. Sleep quality and duration and frailty in older adults: a systematic review - Frontiers (Highlights reliance on subjective measures and inconsistent results)

Frequently Asked Questions (FAQ)

Common questions about Oldren (FAQ)

Q: Is Oldren a type of antibiotic?

No. Oldren is a type of medicine known as a selective aldosterone receptor antagonist. It is used for the management of conditions such as high blood pressure and heart failure, according to official labeling.


Q: How quickly do people usually start to feel the effects of Oldren?

According to the official product information for treating high blood pressure, the full intended effect, as documented in clinical studies, is generally seen within four weeks of starting therapy. This timeframe reflects when the medicine’s actions are fully realized.


Q: Does Oldren have a generic version available?

Yes, regulatory information indicates that the active ingredient in Oldren, Eplerenone, is available as a generic drug product.


Q: What is the difference between Oldren and the similar-sounding medication I saw?

Oldren's active ingredient is distinguished as a selective aldosterone receptor antagonist. This means it is highly targeted and generally limits interaction with other hormone receptors in the body, which is a key distinguishing feature compared to older, related non-selective medicines.


Q: Does Oldren affect blood pressure?

Yes, Oldren is formally classified as an antihypertensive agent. Official labeling indicates the medicine is used for the management of hypertension (high blood pressure).


Q: Is Oldren a controlled substance or addictive?

Official regulatory bodies do not classify this medicine as a controlled substance. This means the drug is not subject to the special legal restrictions applied to medications with potential for abuse or dependence.


Q: Is Oldren available over the counter in some countries?

Regulatory guidelines in authorized regions consistently classify Oldren as a prescription-only medication. It is not available for purchase over the counter.


Q: Why does Oldren's official information mention a risk of XYZ side effect?

Regulatory agencies require all drug manufacturers to disclose every safety risk. This includes both common and serious adverse reactions that were observed during the clinical trial process, ensuring transparency and informed patient use of the medicine.


Q: Are there different strengths of Oldren tablets?

Yes, regulatory documentation confirms that the tablets are available in different strengths, typically 25 mg and 50 mg.


Q: Does taking Oldren affect my ability to drive or operate machinery?

Official documents warn that this medicine may cause dizziness. Official documents state that if dizziness occurs, individuals should avoid driving or operating machinery.


Q: Is it normal to feel a mild headache when first starting Oldren?

Headache is listed in official documents as a possible adverse reaction reported in clinical studies.


Q: Can Oldren be used by people who have diabetes?

Regulatory labeling indicates that the medicine is contraindicated (prohibited) for use in patients with high blood pressure who also have Type 2 diabetes and have microalbuminuria. The specific eligibility for other diabetes contexts is not outlined in this general contraindication.


Q: Are there any long-term effects of taking Oldren that studies have examined?

While specific long-term outcome studies are less clear, regulatory documents confirm the drug produces sustained changes in the body's chemistry. This includes elevated levels of plasma renin and serum aldosterone, which aligns with its long-term biochemical action.


Q: What does the FDA label say about using Oldren during pregnancy?

The FDA label notes that there are insufficient data from human pregnancy studies to establish a drug-associated risk. Official documents state that the medicine is typically used during pregnancy only if the potential benefit is determined to outweigh the potential risk to the fetus.


Q: Why is there a specific warning about grapefruit juice in the Oldren leaflet?

The warning exists because grapefruit juice is documented to interact with the way the body processes the medicine. It is a strong inhibitor of a key metabolic enzyme, which can significantly increase the level of the drug in the blood and is associated with an increased risk of elevated potassium levels.


Q: Has Oldren been approved for use in children?

No. Official regulatory labeling explicitly states that the safety and effectiveness of this medicine have not been established in the pediatric population (children and adolescents).


Q: Does Oldren interfere with blood tests or lab results?

Yes. Regulatory documents and clinical trial findings show that the medicine is documented to potentially cause increases in certain laboratory values. Specifically, increases in serum potassium and serum creatinine levels have been observed.


Q: Is Oldren often used in combination with other drugs?

Yes. Regulatory labeling for the treatment of high blood pressure indicates that the medicine may be used alone or in combination with other antihypertensive agents designed to lower blood pressure.


Q: What is the shelf life or expiry period for Oldren?

Official regulatory documentation, such as the FDA review, noted that an initial approval was granted for an eighteen-month expiration-dating period for the drug product.


Q: Are there studies about Oldren's effectiveness in different patient groups?

Yes. Regulatory documents include data from pharmacokinetic studies that specifically examined how the drug is handled by the body in various patient groups. This includes individuals with differing levels of renal (kidney) and hepatic (liver) impairment.


Q: Why do some people report feeling tired after taking Oldren?

Excessive tiredness (fatigue) and flu-like symptoms are listed in official drug documents as possible side effects. These reactions were observed during clinical studies.


Q: Can Oldren be taken with common vitamins or supplements?

Regulatory labeling includes a specific warning that potassium supplements should be avoided due to the increased risk of high blood potassium. Official guidance generally recommends that patients disclose all vitamins and supplements to their healthcare provider.


Q: Are there any specific foods or drinks that should be avoided while taking Oldren?

Yes. Official sources explicitly describe an interaction with grapefruit or grapefruit juice. This food interaction may increase the amount of medicine in the bloodstream, which is associated with an increased risk of elevated potassium levels.


Q: Can Oldren be used by older adults?

Official guidelines permit the use of the drug in geriatric patients. However, regulatory labeling specifically notes that older adults can be at greater risk for some adverse effects, and use in this population may require caution.


Q: Does Oldren interact with common pain relievers like ibuprofen?

Yes. Nonsteroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers such as ibuprofen, are documented to increase the risk of hyperkalemia (high blood potassium) when taken with this medicine.


Q: Can Oldren be taken if I am already using an herbal product?

Regulatory information specifically addresses an interaction between this medicine and the herbal product St. John's Wort. As a general rule, official guidance advises that patients should discuss all herbal products with a healthcare provider.


Q: Does Oldren require a special prescription or monitoring?

The medicine is prescription-only. Official regulatory documents indicate that patient monitoring is necessary, specifically blood tests for serum potassium and renal function, before starting and routinely during the initial phase of therapy.

How should Oldren be stored and disposed of?

Official Storage and Disposal Guidelines

Prescription medication should be stored strictly according to official regulatory requirements to ensure quality and safety. Medication must be kept out of reach and sight of children and pets in a secure location.

Storage Component Requirement (Regulatory Basis)
Temperature & Environment Store in a cool, dry place. Protect from excessive heat, moisture, and light.
Container & Integrity Keep in the original container with the safety lock secured. Follow the expiration date on the label.

For disposal, the primary method is to use an official drug take-back program. If a program is unavailable, medication not on the FDA's 'flush list' should be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. It is mandatory to scratch out all personal identifying information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oldren found in:

A-Z Index: